Recently, 15 mg tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, reduced the body weight of patients with obesity by 20.9% from baseline compared with placebo in the SURMOUNT-1 trial [15]. The gene discussed is GIP; the disease is obesity disorder.